Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Hess, Georg [1 ]
Kang, Lisa [2 ]
Moran, Padraig J. [3 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Dublin, PA, Ireland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1165
页数：1
相关论文
共 50 条
  • [11] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    G Hess
    U Keller
    C W Scholz
    M Witzens-Harig
    J Atta
    C Buske
    S Kirschey
    C Ruckes
    C Medler
    C van Oordt
    W Klapper
    M Theobald
    M Dreyling
    Leukemia, 2015, 29 : 1695 - 1701
  • [12] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    Hess, G.
    Keller, U.
    Scholz, C. W.
    Witzens-Harig, M.
    Atta, J.
    Buske, C.
    Kirschey, S.
    Ruckes, C.
    Medler, C.
    van Oordt, C.
    Klapper, W.
    Theobald, M.
    Dreyling, M.
    LEUKEMIA, 2015, 29 (08) : 1695 - 1701
  • [13] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Neuhof, A.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    Oncology Research and Treatment, 2015, 38 : 66 - 67
  • [14] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Neuhof, A.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S656 - S656
  • [15] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Herzberg, C.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S850 - S851
  • [16] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 144 - 145
  • [17] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
    Krekeler, G.
    Herzberg, C.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2013, 36 : 139 - 140
  • [18] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [19] Efficacy and safety of zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a systematic review
    Santoso, A. Febrian
    Margouw, R. Relia
    Maulidia, S. Azrianindita
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1341 - S1341
  • [20] Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma
    Jurczak, Wojciech
    Ramanathan, Sundra
    Giri, Pratyush
    Romano, Alessandra
    Mocikova, Heidi
    Clancy, Jill
    Lechuga, Mariajose
    Casey, Michelle
    Boni, Joseph
    Giza, Agnieszka
    Hess, Georg
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 670 - 678
12345